Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $1.64M fell 40.9% year over year, ahead of the -51.5% change in trailing-twelve-month other income / expenses. Sequentially, it rose 10.9% from the prior quarter. Over 3 fiscal years it compounded at +158.9% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -40.9% holds above the trailing-twelve-month pace of -51.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 8.52M USD
- Year-over-year change
- -43.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.52M | -43.7% |
| FY2024 | 2024-12-31 | 15.13M | +641.5% |
| FY2023 | 2023-12-31 | 2.04M | +315.5% |
| FY2022 | 2022-12-31 | 491K | +12375.0% |
| FY2021 | 2021-12-31 | (4K) | — |
Other Income / Expenses vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 other income / expenses of $7.39M is the 5th highest of the 11 companies compared; the peer median is $5.75M.
- Its year-over-year change of -51.5% is the 9th highest of 10, against a peer median of -3.2%.
- Over three fiscal years its annual growth of +158.9% compares with a peer median of +55.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46M | -3.2% | — | — | |
| LTM Mar 2026 | $14.02M | -40.6% | +13.7% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $10.28M | +47.5% | +96.1% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.41M | +109.1% | — | — |
| LTM Mar 2026 | $7.39M | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $6.16M | -32.3% | — | 15.9% | |
| LTM Mar 2026 | $5.34M | +140.8% | +66.0% | — | |
| LTM Mar 2026 | $3.97M | -46.9% | +55.6% | — | |
| LTM Mar 2026 | $1.86M | +124.8% | — | 372.3% | |
| LTM Mar 2026 | $1.43M | — | -50.1% | 155.2% | |
| LTM Mar 2026 | -$54.54M | -309.6% | — | 175948.4% | |
| Peer median (excluding KYTX) | $5.75M | -3.2% | +55.6% | 263.8% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| Weighted Avg Shares | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
| Weighted Avg Shares (Diluted) | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.